Member Info for PL75

It’s the value of this business on a net present value basis. For some reason the market is thick as mince. We’re nowhere near it, so I’m not sure what the excitement is

So there’s over 3x upside once we’re $51bn. Maybe put a couple of quid aside and wait until we’re at that stage. Don’t commit too early

Yeah **** you 137 you ************* **** of a ****** ***** ****

Interesting read, thanks

They’ve censored ‘look at someone or something with one or both eyes partly closed in an attempt to see more clearly or as a reaction to strong light’. Bonkers.

up, down or sideways. if you’re capable of s*****ing you can figure out what the brown crayon will say. clue, he’s got absolutely no idea. start a thread in general.

I mean, it wouldn't be anything else other than that ******* **** of a ****** **** ******

I can't buy on HL

I doubled my investment to 20% off the back of it. Thanks sheppy, I'm already quids in.

I was surprised it didn’t get more excitement to be fair, it’s a very significant development.

‘when a new experimental therapy is expected to provide a substantial benefit over existing treatments’

Ticked that box. Essentially when the FDA gives the go ahead, we’re pretty much in phase 2, safety and efficacy from the first phase are in the bag.

Again, I don’t think you’re being fair to our colleagues in the boiler room Timster. Poor eggy is running out of options for his dewamping. None of it goes near the fundamentals anymore as they’re no angle. It undeniably works. The actions off the back of the emerging data all point to a confident business heading towards the promised land. We’re on the home straight, risks are gone and joyously the price is immune so we can enjoy cheap ‘top ups’ a plenty.

Aaah, but why is the price immune they’ll scream in to the abyss, there must be a reason… nope, the market is thick as mince. Think Lartruvo. Massive STS market. Think Point. Takeovers with no inkling. Great times for a LTH, have a lovely day all

Spotted by the eagle eyed gmcc…

Pleased to see you catch up JT! Alan said this change was due to clear efficacy in 1a. They found it works when it isn’t even supposed to. Imagine the results from the ‘short’ study….

Tongue in cheek, but appreciate the reply. Completely agree that they’re seeing some great data to crack on.

Reckon a classic, nice Ford Escort with a body kit would suit you

RD, what do you mean by ‘recovery time’. They can’t tell the difference between patients that have been dosed and those who haven’t.

Be fair Timster, must be tricky remembering all the various aliases / personality disorders when you're a scumbag with numerous accounts

Originally he said end of Q4 or before the end of the year, so I reckon we'll see it late Feb if we're lucky. Then said it was C6 and emerging C7 so that sounds like they're working on it straight away, so it'll turn up out of the blue - much like Point's takeover, these things just happen with zero warning at all. That's why it's fabulous being a LTH, have a lovely day

So, big pharma are very much aware of the tech and potential. Just a matter of time.

Pre|CISION works.

Thanks for sharing thevid. Regarding ODD, it’s designed to be lucrative and worthwhile to encourage investment in to developing drugs for rarer diseases. By accident or more likely design, we’re rapidly heading towards an extremely valuable first pre|cision asset

Thanks to our resident FDA exspurt for that definitive decision.

Meanwhile…. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval

“For example, instead of having to wait to learn if a drug actually extends survival for cancer patients, the FDA may approve a drug based on evidence that the drug shrinks tumors, because tumor shrinkage is considered reasonably likely to predict a real clinical benefit.”

We’ve got one example in the bag, more to come in the next 9 months hopefully. Especially when considering fortnightly dosing. Stop dreaming? Wake up and smell the coffee, we could be closer than you think.